|
Match
|
Document |
Document Title |
|
|
6013252 |
Method promoting conception by administering IL-8 or MCAF
Leukocyte chemotactic factors such as interleukin-8 and MCAF, and inductive substances therefor were revealed to have proconceptive activities. These activities include promoting ovum growth and...
|
|
|
6008188 |
Cytokine potentiator and pharmaceutical formulation for cytokine administration
A cytokine activity enhancer comprising an ethanolamine derivative of the following general formula (I) or a salt thereof, or comprising it along with cytokine or a cytokine production promoter;...
|
|
|
6004548 |
Analogs of pluripotent granulocyte colony-stimulating factor
Disclosed are novel polypeptides possessing part or all of the primary structural conformation and one or more of the biological properties of a mammalian (e.g., human) pluripotent granulocyte...
|
|
|
6001606 |
Polynucleotides encoding myeloid progenitor inhibitory factor-1 (MPIF-1) and polypeptides encoded thereby
There are disclosed therapeutic compositions and methods using isolated nucleic acid molecules encoding a human myeloid progenitor inhibitory factor-1 (MPIF-1) polypeptide (previously termed MIP-3...
|
|
|
6001806 |
Interferon stimulating protein and uses thereof
This invention relates to the use of the baculovirus glycoprotein, Interferon Stimulating Protein (ISP) (also known as gp67, gp64 EFP, or gp64), or the gene sequence encoding ISP, to stimulate...
|
|
|
6001803 |
Composition of c-kit ligand, GM-CSF, and TNF-α and method of use
A pharmaceutical composition which comprises the c-kit ligand (KL) purified by applicants or produced by applicants' recombinant methods in combination with other hematopoietic factors and a...
|
|
|
6001649 |
Chemokine NC28 (monocyte chemotactic protein-3, MCP-3) polypeptides and their recombinant production
A new chemotactic cytokine, NC28 or Monocyte Chemotactic Protein-3 (MCP-3), is provided. Fragments of the cytokine comprising its 13 C-terminal amino acids also exhibit chemotactic activity. The...
|
|
|
5997857 |
Co-administration of interleukin-3 mutants with colony stimulating factors
The present invention relates to human interleukin-3 (hIL-3) variant or mutant proteins (muteins) functionally co-administered with other colony stimulating factors (CSF), cytokines, lymphokines,...
|
|
|
5997860 |
Ex-vivo expansion of stem cells using combinations of interleukin-3 (IL-3) variants and other cytokines
The present invention relates to human interleukin-3 (hIL-3) variant or mutant proteins (muteins) functionally co-administered with a other colony stimulating factors (CSF), cytokines, lymphokines,...
|
|
|
5998378 |
Compositions for the inhibition of TNF hormone formation and uses thereof
Compounds having proteolytic inhibitory activity useful for treating diseases, particularly as applied to the treatment of sepsis, AIDS or autoimmune diseases, resulting from a decrease in the...
|
|
|
5998370 |
Agents for the prevention and/or treatment of radiation-induced disorders by administrating TCF-II
The use of Tumor Cytotoxic Factor-II (TCF-II) enables the prevention and/or treatment of radiation-induced disorders.
|
|
|
5993810 |
Method of softening or ripening the cervix of a female mammal using collagenase
The present invention relates to the use of collagenase and/or one more substances which stimulate the production of naturally occurring collagenase in the cervix to induce labor in a female...
|
|
|
5993798 |
Oncoinhibin and methods of pharmaceutical use
The present invention provides a novel human cytokine termed Oncoinhibin. The protein Oncoinhibin is secreted by human erythroblastoid cells, has a molecular weight of approximately 28 kDa and...
|
|
|
5989538 |
Mpl ligand analogs
Mpl ligand analogs having one or more changed glycosylation sites as compared to a naturally occurring mpl ligand sequence of a corresponding number of amino acids are disclosed. The invention also...
|
|
|
5989537 |
Methods for stimulating granulocyte/macrophage lineage using thrombopoietin
Methods for stimulating granulocyte/macrophage lineage cells using thrombopoiet in are provided. The methods provided may be used to stimulate granulocyte/macrophage progenitors and neutrophils in...
|
|
|
5985261 |
Use of thioredoxin-like molecules for induction of MnSOD to treat oxidative damage
A method to increase cellular MnSOD production in an animal to treat oxidative damage by administering a protein having a thioredoxin active-site in reduced state. A composition and a method to...
|
|
|
5985263 |
Substantially pure histidine-linked protein polymer conjugates
Substantially pure histidine-linked protein-polymer conjugates and processes for their preparation are disclosed. The processes include contacting a protein with an activated polymer under...
|
|
|
5985613 |
Use of an "immunodeficiency-virus suppressing lymphokine (ISL) "to inhibit the replication of viruses, in particular of retroviruses
An isolated polypeptide which inhibits the replication of retroviruses in peripheral blood lymphocytes and i) is encoded by the DNA sequence shown in SEQ ID NO: 1 or complementary sequences; or ii)...
|
|
|
5985290 |
Purified pancreatic tumor cell lines and related compositions and method
The present invention provides a method of treating cancer comprising (a) obtaining a tumor cell line, (b) modifying the tumor cell line to render it capable of producing an increased level of a...
|
|
|
5981472 |
Methods for treating diseases
Herein is provided a method for identifying extreme stressors which may become causative agents responsible for syndromes characterized by premature progressive cell loss or cell over growth in an...
|
|
|
5980887 |
Methods for enhancing angiogenesis with endothelial progenitor cells
In accordance with the present invention, EC progenitors can be used in a method for regulating angiogenesis, i.e., enhancing or inhibiting blood vessel formation, in a selected patient and in some...
|
|
|
5977323 |
Method of purifying Gro β or Gro α protein using antibodies
Two novel cytokines which are involved in an inflammatory response (inflammatory cytokines) are disclosed. The inflammatory cytokines have been isolated from activated peripheral blood, preferably...
|
|
|
5976523 |
Method for healing compromised tissues using pyrimidine derivatives
The present invention provides a method for the screening of a wound-healing agent, which comprises determining a substance to be active as a wound-healing agent on the basis of potentiation or...
|
|
|
5977310 |
Peg-modified HGF
This invention relates to a PEG-modified HGF (Hepatocyte Growth Factor), namely HGF modified by polyethylene glycol. The PEG-modified HGF of the invention has a prolonged clearance in vivo,...
|
|
|
5976522 |
Lymphocyte chemoattractant factor and uses thereof
Disclosed is a substantially pure antibody which specifically binds a LCF polypeptide and methods of using such antibodies.
|
|
|
5972331 |
Crystalline interferon alpha for pulmonary delivery and method for producing the same
A method to prepare crystalline interferon alpha suitable for aerosol formulation either for systemic or topical (inhaled) drug delivery. The bioavailable interferon is in the form of crystalline...
|
|
|
5968548 |
Use of liposome encapsulated cirprofloxacin as an immunotherapeutic drug
Liposome-encapsulated quinolones and specifically liposome-encapsulated ciprofloxacin dramatically enhances macrophage functions, induces NO production and augments the production of cytokines,...
|
|
|
5968905 |
Stimulation of nerve growth and/or vitality
The protein, cholinergic neuronal differentiation factor (CDF), also known as leukemia inhibitory factor (LIF), is described, together with the use of the polypeptide to stimulate neuron growth and...
|
|
|
5968501 |
Hepatocyte growth factor--induced proliferation and differentiation of erythroid cells
Hepatocyte growth factor stimulates proliferation and differentiation of hematopoietic cells, most preferably burst-forming unit-erythroid cells. The hepatocyte growth factor may be obtained from...
|
|
|
5961969 |
Stable circulating histamine levels
Methods for obtaining beneficial stable levels of circulating histamine are disclosed for use in methods for enhancing natural killer cell cytotoxicity. In such methods, a beneficial level of...
|
|
|
5958413 |
Use of antibodies to TNF or fragments derived thereof and xanthine derivatives for combination therapy and compositions therefor
A combined preparation for simultaneous combined, simultaneous separate, or sequential use in the therapy of prophylaxis of disorders associated with undesirable high levels of TNF, e.g. septic or...
|
|
|
5945511 |
Class II cytokine receptor
Novel receptor polypeptides, polynucleotides encoding the polypeptides, and related compositions and methods are disclosed. The polypeptides comprise an extracellular domain of a cell-surface...
|
|
|
5945096 |
Method for recombinant production of biologically active polypeptides
Polypeptides, polynucleotides, fragments thereof, and monoclonal antibodies thereto are provided for antigen-specific and antigen-non-specific glycosylation inhibiting factor and a method for...
|
|
|
5942220 |
Inhibitor of cytokine activity and applications thereof
Described herein are compositions that have prophylactic or therapeutic applications for disease resulting from the production of cytokines, and preferably the cytokine IL-6, wherein the...
|
|
|
5942222 |
Methods of treating granulocyte-macrophage progenitor cell-derived blood cell dysfunction
The present invention relates to the identification of promoters of myelopoietic blood cell production. In particular, an agent has been discovered that enhances myelopoietic colony stimulating...
|
|
|
5942221 |
Recombinant primate granulocyte macrophage-colony stimulating factor
A method for preparing and isolating a transformation vector containing CSF/cDNA is described. The method comprises: preparing RNA from a cell that produces CSF; preparing polyadenylated messenger...
|
|
|
5939388 |
Methods of administering BMP-5 compositions
Purified BMP-5 proteins and processes for producing them are disclosed. The proteins may be used in the treatment of bone and/or cartilage defects and in wound healing and related tissue repair.
|
|
|
5939063 |
Modified forms of granulocyte macrophage-colony stimulating factor as antagonists
The present invention relates to modified and variant forms of haemopoietic growth factors (HGF) capable of acting as antagonists to the corresponding native haemopoietic growth factors and their...
|
|
|
5935565 |
Method for increasing the level of stem cells in peripheral blood
A pharmaceutical composition which comprises the c-kit ligand (KL) purified by applicants or produced by applicants' recombinant methods in combination with other hematopoietic factors and a...
|
|
|
5935929 |
Methods for treating interstitial lung disease by using interleukin-9 and its antagonists
A method for the treatment and prevention of immune disorders and fibrosis associated disorders is disclosed. The method involves administering interleukin-9 in an effective amount to the subject....
|
|
|
5936067 |
Macrophage inflammatory protein variants
The present invention provides a Stem Cell Inhibitor (SCT) protein which comprises at least one amino acid alteration from its active form which protein does not significantly aggregate but which...
|
|
|
5932208 |
Compositions and methods for the use of such compositions in human therapeutics, characterized by the association of a muramyl peptide with a cytokine
A therapeutical composition for use in humans, comprising a combination of at least one natural or recombinant and preferably human cytokine with at least one muramyl peptide selected from those...
|
|
|
5932207 |
Complex active ingredient for the production of biological parts, especially organs for living organisms: method for the production of the same and its use
An active ingredient complex to promote the growth of cells, tissue and/or organs is disclosed. The complex comprises the following form ingredients: a structural component, a recruiting component,...
|
|
|
5932537 |
Method for attenuating a cellular response to IL-1
Medicaments and methods of using the same are disclosed for treating or preventing diseases resulting from undesirable cell adhesion of IL-1 receptor positive cells to biological materials,...
|
|
|
5932703 |
Macrophage derived chemokine and chemokine analogs
The present invention provides purified and isolated polynucleotide sequences encoding a novel human macrophage-derived C--C chemokine designated MDC, and polypeptide analogs thereof. Also provided...
|
|
|
5928635 |
Process for producing active agent complexes
The invention relates to a process for producing active agent complexes from at least one initial complex having components in which the initial complex is caused at least partially to assume a...
|
|
|
5928639 |
Immunotherapy of cancer with allogeneic lymphocytes
Methods have been discovered for treating minimal residual disease following removal of most or a substantial fraction of malignant cells from a cancer patient. An autologous stem cell transplant...
|
|
|
5925343 |
Canine granulocyte macrophage colony stimulating factor
Canine granulocyte macrophage colony stimulating factor (caGM-CSF) corresponding to that found in canine serum and/or tissues, structural variants thereof, genes that encode these materials,...
|
|
|
5922573 |
IL-1 receptor antagonists with enhanced inhibitory activity
DNA molecules that code for IL-1 antagonists with improved biological activity arc described. DNA molecules coding for improved IL-1 antagonists inserted into expression vectors and host cells...
|
|
|
5919757 |
Aqueous pharmaceutical preparations of G-CSF with a long shelf life
Aqueous pharmaceutical preparations of G-CSF are disclosed that are stable on storage and a buffer selected from the group consisting of a salt of citrate, maleate, a combination of phosphate and...
|